Certara Inc. (CERT)
BMV
Closed
Oct 5, 2026
Day's Range
254.0052 wk Range
254.00Overview - CERT - Certara Inc.
Key Statistics
Valuation
Enterprise Value
711.33B
P/E (Trailing)
‪-25,400.00‬
PEG Ratio
‪-7.25‬
Price / Sales (TTM)
‪75.84‬
Price / Book
‪1.82‬
EV / EBITDA
‪412.32‬
Profitability
Gross Margin
‪62.34%‬
Profit Margin
‪-16.21%‬
Operating Margin
‪-0.21%‬
Return on Assets
‪0.76%‬
Return on Equity
‪-2.20%‬
Ownership
Shares Outstanding
152.49M
Float
111.95M
Held by Insiders
‪2.72%‬
Held by Institutions
‪112.87%‬
Price stats
Beta
‪1.40‬
50-Day Avg
‪254.00‬
200-Day Avg
‪254.00‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - CERT - Certara Inc.
Peers - CERT - Certara Inc.
Peer Comparison
Compared with companies in Health Information Services listed on BMV.
- CERTBMVCertara Inc.38.74BMarket Cap+0.00%52-week change-25400.00P/E (Trailing)‪-16.21%‬Profit Margin
- VEEVBMVVeeva Systems Inc.720.15BMarket Cap-2.82%52-week change45.87P/E (Trailing)‪29.34%‬Profit Margin
- KERNBMVKering SA613.13BMarket Cap+25.57%52-week change51.28P/E (Trailing)‪-1.47%‬Profit Margin
- TEMBMVTempus AI Inc Class A Common Stock277.59BMarket Cap+4.84%52-week change-1084.40P/E (Trailing)‪-17.76%‬Profit Margin
- TXGBMV10x Genomics Inc.211.50BMarket Cap+83.61%52-week change-4638.06P/E (Trailing)‪-12.17%‬Profit Margin
- HQYBMVHealthEquity, Inc.177.83BMarket Cap+0.00%52-week change84.02P/E (Trailing)‪17.36%‬Profit Margin
- OMCLBMVOmnicell, Inc.34.72BMarket Cap-26.32%52-week change52.35P/E (Trailing)‪3.13%‬Profit Margin
Profile Summary - CERT - Certara Inc.
About
Certara, Inc. is a global leader in biosimulation science, technology, and consulting services that transform drug development through model-informed drug development (MIDD). The company provides proprietary biosimulation platforms, software products, and expert consulting services designed to help biopharmaceutical…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
